Targeting Inflammaging In Alzheimer’S Disease: Molecular Pathways And Emerging Pharmacotherapies
As we age, our bodies can experience a state of chronic, low-grade inflammation, a process scientists call “inflammaging.” This isn’t just a harmless side effect of getting older; new research suggests it plays a crucial role in the development and progression of Alzheimer’s disease. Instead of being a passive bystander, inflammaging actively contributes to the disease by speeding up the accumulation of harmful proteins like amyloid-beta and tau, which are hallmarks of Alzheimer’s, and damaging the connections between brain cells, known as synapses.
Understanding how inflammaging fuels Alzheimer’s involves looking at several key biological pathways. These include the NLRP3 inflammasome, which is a complex of proteins that triggers inflammation; impaired autophagy, a cellular “recycling” process that removes damaged components; TREM2 signaling, a pathway involved in immune cell function in the brain; and the cGAS-STING pathway, which detects abnormal DNA and initiates immune responses.
The good news is that by understanding these pathways, researchers are identifying new ways to fight Alzheimer’s. Emerging treatments aim to specifically target these inflammatory processes. This includes drugs that inhibit the NLRP3 inflammasome, agents that clear out senescent (aging and dysfunctional) cells, and compounds that enhance autophagy. These approaches offer a promising new direction, potentially complementing existing treatments that focus on amyloid-beta, by directly addressing the persistent inflammatory environment in the aging brain and potentially slowing down the disease’s progression.
Source: link to paper